Atezolizumab

About

Therapy type: Immunotherapy

Therapy strategy: PD-1/PD-L1 inhibition

Mappings

NCI Thesaurus: Atezolizumab (coding:ncit:C106250)

RxNorm: atezolizumab (coding:rxcui:1792776, coding:omop:42629079)

SNOMED: Atezolizumab (coding:sctid:719371003, coding:omop:36714233)

View API

Therapeutic response

Precision oncology relationships for therapeutic response involving this therapy.

Organizations Biomarkers Cancer types Therapies
FDA (1) PD-L1 >= 1% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) HC (1) PD-L1 >= 50% Non-Small Cell Lung Cancer Atezolizumab
FDA (1) PD-L1 >= 10% TIIC Non-Small Cell Lung Cancer Atezolizumab
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Bevacizumab, Carboplatin, Paclitaxel
FDA (1) Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab, Carboplatin, Paclitaxel
FDA (1) EGFR Somatic variants Non-Small Cell Lung Cancer Atezolizumab
FDA (1) v::ALK Non-Small Cell Lung Cancer Atezolizumab
FDA (1) BRAF p.V600E Melanoma Atezolizumab, Cobimetinib, Vemurafenib
FDA (1) BRAF p.V600K Melanoma Atezolizumab, Cobimetinib, Vemurafenib
HC (1) PD-L1 >= 50%, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
HC (1) PD-L1 >= 10% TIIC, Wild type ALK, Wild type EGFR Non-Small Cell Lung Cancer Atezolizumab
HC (1) ER negative, HER2-negative, PD-L1 >= 1%, PR negative Invasive Breast Carcinoma Atezolizumab, Nab-paclitaxel